AzTrials
AzTrials

Crohn DiseasePhase 3NCT03464097

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

A Phase 3 study testing Ozanimod in people with Crohn Disease, run by Celgene at 765 sites in 49 countries.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

This is a study to demonstrate the effect of oral ozanimod as maintenance therapy in participants with moderately to severely active Crohn's Disease. Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Crohn Disease
What is being tested?
Ozanimod
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
550 participants
Where
765 sitesin 49 countries
Study dates
27 Jun 2018to 3 Oct 2024
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Fulfilled the inclusion criteria at time of entry into the induction study and completed the week 12 efficacy assessments of the induction study
  • In clinical response and/or clinical remission and/or an average daily stool frequency score ≤ 3 and an average abdominal pain score ≤ 1 with abdominal pain and stool frequency no worse than baseline at Week 12 of the Induction Study

Who cannot join

  • Partial or total colectomy, small bowel resection, or an ostomy since day 1 of the induction studies or has developed a symptomatic fistula
  • Had a rectal steroid therapy, rectal 5-aminosalicylates, parenteral corticosteroids, immunomodulatory agents, investigational agents or apheresis
  • Other protocol-defined inclusion/exclusion criteria apply

Trial locations and contacts

765 sites in 49 countries.

765 sites in 49 countries

United States188 sites

  • Local Institution - 017

    Asheville, North Carolina, 28801

  • Consultative Gastroenterology

    Atlanta, Georgia, 30308

  • Local Institution - 037

    Atlanta, Georgia, 30322

  • Local Institution - 220

    Atlanta, Georgia, 30322

  • Local Institution - 222

    Atlanta, Georgia, 30322

  • Local Institution - 019

    Atlanta, Georgia, 30342

  • Local Institution - 063

    Atlanta, Georgia, 30342

  • Local Institution - 158

    Austin, Texas, 78742

  • Local Institution - 278

    Baltimore, Maryland, 21224

  • Local Institution - 020

    Baton Rouge, Louisiana, 70809

  • Great Lakes Medical Research, LLC

    Beachwood, Ohio, 44122

  • Local Institution - 182

    Bristol, Connecticut, 06010

  • Local Institution - 225

    Bristol, Connecticut, 06010

  • Local Institution - 144

    Brooklyn, New York, 11235

  • Local Institution - 284

    Camarillo, California, 93012

  • Local Institution - 191

    Caro, Michigan, 48723

  • Local Institution - 129

    Catonsville, Maryland, 21228

  • Local Institution - 289

    Charleston, South Carolina, 29425

  • Local Institution - 152

    Charlotte, North Carolina, 28204

  • Local Institution - 055

    Charlotte, North Carolina, 28207

  • Local Institution - 156

    Charlotte, North Carolina, 28209

  • Local Institution - 142

    Chestnut Hill, Massachusetts, 02467

  • Local Institution - 194

    Chicago, Illinois, 60612

  • Local Institution - 036

    Chicago, Illinois, 60622

  • Local Institution - 022

    Chicago, Illinois, 60637

  • Sharp Chula Vista Medical Center

    Chula Vista, California, 91911

  • Local Institution - 291

    Cincinnati, Ohio, 45219

  • Local Institution - 062

    Clearwater, Florida, 33756-3839

  • Clinical Research of West Florida

    Clearwater, Florida, 33765

  • South Lake Pain Institute

    Clermont, Florida, 34711

  • Local Institution - 018

    Cleveland, Ohio, 44195

  • Iowa Digestive Disease Center

    Clive, Iowa, 50325

  • Local Institution - 065

    Colorado Springs, Colorado, 80907

  • Local Institution - 074

    Columbus, Georgia, 31904

  • American Research Institute Inc

    Cutler Bay, Florida, 33157

  • Local Institution - 170

    Dayton, Ohio, 45417

  • Local Institution - 143

    Decatur, Georgia, 30030

  • Universal Axon Clinical Research

    Doral, Florida, 33166

  • Riverside Clinical Research

    Edgewater, Florida, 32132

  • Local Institution - 215

    Englewood, New Jersey, 07631

  • Local Institution - 092

    Evansville, Indiana, 47714

  • Local Institution - 034

    Fort Sam Houston, Texas, 78234

  • Local Institution - 218

    Gainesville, Florida, 32608

  • Local Institution - 189

    Gainesville, Virginia, 20155

  • Local Institution - 039

    Garden Grove, California, 92843

  • Local Institution - 282

    Glen Burnie, Maryland, 21061

  • Aurora Health Care Aurora Research

    Grafton, Wisconsin, 53024

  • Local Institution - 009

    Great Neck, New York, 11021

  • Local Institution - 133

    Greenville, North Carolina, 27834

  • Local Institution - 054

    Hartsdale, New York, 10530

  • Local Institution - 197

    Hershey, Pennsylvania, 17033

  • Local Institution - 203

    Hialeah, Florida, 33010

  • Floridian Clinical Research LLC

    Hialeah, Florida, 33016

  • Harmony Medical Research Institute

    Hialeah, Florida, 33016

  • Local Institution - 049

    Hilliard, Ohio, 43026

  • Local Institution - 179

    Hollywood, Florida, 33021

  • Vista Health Research

    Homestead, Florida, 33033

  • CroNOLA LLC

    Houma, Louisiana, 70360

  • Local Institution - 056

    Houston, Texas, 77030

  • Local Institution - 150

    Houston, Texas, 77030

  • Biopharma Informatic Inc. Research Center

    Houston, Texas, 77043

  • Centex Studies, Inc.

    Houston, Texas, 77058

  • GI Specialists of Houston

    Houston, Texas, 77070

  • Local Institution - 303

    Houston, Texas, 77074

  • Local Institution - 088

    Houston, Texas, 77084

  • Local Institution - 196

    Houston, Texas, 77089

  • Gulf Coast Research Group LLC

    Houston, Texas, 77098

  • Local Institution - 115

    Idaho Falls, Idaho, 83404

  • Local Institution - 033

    Indianapolis, Indiana, 46202

  • Local Institution - 274

    Jackson, Mississippi, 39216

  • Local Institution - 167

    Kalamazoo, Michigan, 49008

  • Local Institution - 198

    Kansas City, Missouri, 64111

  • SIH Research

    Kissimmee, Florida, 34759

  • Local Institution - 089

    La Crosse, Wisconsin, 54601

  • Ucsd Medical Center

    La Jolla, California, 92037

  • San Diego Clinical Trials

    La Mesa, California, 91942

  • Centex Studies, Inc.

    Lake Charles, Louisiana, 70601

  • Clinical Trials of SW Louisiana LLC

    Lake Charles, Louisiana, 70601

  • Local Institution - 297

    Lakewood, Colorado, 80228

  • Local Institution - 010

    Lancaster, California, 93534

  • Local Institution - 016

    Largo, Florida, 33777

  • Internal Medicine Specialists

    Las Vegas, Nevada, 89145

  • Local Institution - 040

    Lebanon, New Hampshire, 03756

  • Local Institution - 155

    Lexington, Kentucky, 40536-0298

  • Local Institution - 067

    Lighthouse PT, Florida, 33064

  • Local Institution - 061

    Los Angeles, California, 90027

  • Southern California Research Institute Medical Group, Inc.

    Los Angeles, California, 90045

  • Matrix Clinical Research Inc

    Los Angeles, California, 90048

  • Local Institution - 110

    Los Angeles, California, 90067

  • Local Institution - 030

    Lynchburg, Virginia, 24502

  • Local Institution - 028

    Macon, Georgia, 31201

  • Center For Advanced Gastroenterology

    Maitland, Florida, 32751

  • Local Institution - 298

    Manassas, Virginia, 20110

  • Tandem Clinical Research, LLC

    Marrero, Louisiana, 70072

  • Great Lakes Gastroenterology

    Mentor, Ohio, 44060

  • LMG Research

    Miami, Florida, 33125

  • Local Institution - 199

    Miami, Florida, 33125

  • LCC Medical Research Institute, LLC

    Miami, Florida, 33126

  • Local Institution - 169

    Miami, Florida, 33156

  • Local Institution - 175

    Miami, Florida, 33166

  • Vista Health Research

    Miami, Florida, 33176

  • Local Institution - 044

    Miami Springs, Florida, 33166

  • Local Institution - 141

    Middleburg Heights, Ohio, 44130

  • Local Institution - 095

    Minneapolis, Minnesota, 55455

  • Facey Medical Foundation (Parent)

    Mission Hills, California, 91345

  • ABS Health, LLC

    Mission Viejo, California, 92691

  • Advanced Research for Health Improvement

    Naples, Florida, 34109

  • Local Institution - 121

    Nashville, Tennessee, 37211

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37212

  • Local Institution - 091

    New Haven, Connecticut, 06510

  • Nola Research Works

    New Orleans, Louisiana, 70125

  • Local Institution - 192

    New Port Richey, Florida, 34655

  • Local Institution - 214

    New Smyrna Beach, Florida, 32168

  • Weill Cornell Medical College

    New York, New York, 10010

  • Concorde Medical Group

    New York, New York, 10016

  • Local Institution - 105

    New York, New York, 10021

  • TrialSpark

    New York, New York, 10024

  • Local Institution - 043

    New York, New York, 10075

  • Local Institution - 087

    Norman, Oklahoma, 73071

  • Local Institution - 026

    North Little Rock, Arkansas, 72117

  • Local Institution - 060

    North Massapequa, New York, 11758-1802

  • Local Institution - 228

    North Worcester, Massachusetts, 01655

  • Local Institution - 005

    Novi, Michigan, 48377

  • Alliance Clinical Research

    Oceanside, California, 92056

  • Local Institution - 294

    Oklahoma City, Oklahoma, 73102

  • Local Institution - 208

    Oklahoma City, Oklahoma, 73104

  • Local Institution - 131

    Oklahoma City, Oklahoma, 73112

  • Local Institution - 027

    Orange, California, 92868

  • Circuit Clinical

    Orchard Park, New York, 14127

  • Local Institution - 200

    Orlando, Florida, 32810

  • Local Institution - 076

    Orlando, Florida, 32819

  • Local Institution - 002

    Palmetto Bay, Florida, 33157

  • Palo Alto Center-Palo Alto Medical Foundation Research Institute

    Palo Alto, California, 94304

  • Havana Research Institute LLC

    Pasadena, California, 91105

  • Accurate Clinical Research Inc

    Pasadena, Texas, 77505

  • Holland Center for Family Health

    Peoria, Arizona, 85381

  • Summit Clinical Research, LLC

    Petersburg, Virginia, 23805

  • University of Pennsylvania Cancer Center

    Philadelphia, Pennsylvania, 19104

  • Theia Clinical Research, LLC

    Pinellas Park, Florida, 33781

  • Local Institution - 098

    Port Orange, Florida, 32127

  • Local Institution - 113

    Portland, Oregon, 97239

  • Local Institution - 253

    Providence, Rhode Island, 02904

  • Local Institution - 302

    Raleigh, North Carolina, 27612

  • The Gastroenterology Group

    Reston, Virginia, 20191

  • Local Institution - 006

    Rialto, California, 92377

  • Local Institution - 071

    Richardson, Texas, 75082

  • Local Institution - 072

    Richmond, Virginia, 23249

  • Local Institution - 292

    Riverton, Utah, 84065

  • Local Institution - 172

    Roanoke, Virginia, 24016

  • Local Institution - 045

    Rochester, Minnesota, 55905

  • Sutter Medical Group

    Roseville, California, 95661

  • Local Institution - 280

    Sacramento, California, 95817

  • Local Institution - 025

    Salt Lake City, Utah, 84132

  • Local Institution - 085

    San Antonio, Texas, 78215

  • Local Institution - 223

    San Antonio, Texas, 78229-4894

  • Local Institution - 178

    San Antonio, Texas, 78229

  • Local Institution - 003

    San Diego, California, 92123

  • Local Institution - 281

    San Francisco, California, 94158

  • Local Institution - 202

    Scottsdale, Arizona, 85258

  • Local Institution - 108

    Southfield, Michigan, 48034

  • Local Institution - 007

    Southlake, Texas, 76092

  • Local Institution - 125

    Spokane, Washington, 99204

  • Local Institution - 286

    Springfield, Massachusetts, 01199

  • Local Institution - 029

    St Louis, Missouri, 63110

  • Penn State University Milton S Hershey Medical Center

    State College, Pennsylvania, 16803

  • Virginia Gastroenterology Institute PC

    Suffolk, Virginia, 23434

  • Precision Clinical Research, LLC.

    Sunrise, Florida, 33351

  • Local Institution - 183

    Tampa, Florida, 33612-4799

  • Apex Clinical Research

    Tampa, Florida, 33612

  • Local Institution - 226

    Tampa, Florida, 33612

  • Local Institution - 107

    Tampa, Florida, 33614

  • Local Institution - 149

    Tampa, Florida, 33614

  • Local Institution - 181

    Temple, Texas, 76508

  • Advantage Clinical Trials

    The Bronx, New York, 10468

  • Local Institution - 070

    Topeka, Kansas, 66606

  • Local Institution - 185

    Tulsa, Oklahoma, 74136

  • Local Institution - 217

    Tulsa, Oklahoma, 74137

  • Local Institution - 073

    Tyler, Texas, 75701

  • Advanced Gastroenterology

    Union City, Tennessee, 38261

  • Carle Foundation Hospital

    Urbana, Illinois, 61801

  • Great Lakes Medical Research, LLC

    Warren, Ohio, 44483

  • Local Institution - 114

    Weeki Wachee, Florida, 34607

  • New Hope Research Development

    West Covina, California, 91790

  • Local Institution - 296

    Williamsburg, Virginia, 23188

  • Local Institution - 052

    Winston-Salem, North Carolina, 27103

  • Local Institution - 024

    Worcester, Massachusetts, 01655

  • Local Institution - 301

    Wyoming, Michigan, 49519

  • Local Institution - 300

    Ypsilanti, Michigan, 48197

Other trials in United States

Poland55 sites

  • Local Institution - 820

    Bialystok, 15-276

  • Local Institution - 818

    Bochnia, 32-700

  • Local Institution - 580

    Częstochowa, 42-202

  • Local Institution - 988

    Elblag, 82-300

  • Local Institution - 579

    Gdansk, 80-382

  • Local Institution - 978

    Gdansk, 80-803

  • Local Institution - 577

    Gdynia, 81-537

  • Local Institution - 906

    Jelenia Góra, 58-500

  • Local Institution - 757

    Józefów, 05-410

  • Local Institution - 238

    Katowice, 40-040

  • Local Institution - 578

    Katowice, 40-040

  • Local Institution - 828

    Katowice, 40-660

  • Local Institution - 819

    Katowice, 40-752

  • Local Institution - 817

    Kłodzko, 57-300

  • Local Institution - 815

    Krakow, 30-363

  • Local Institution - 823

    Krakow, 31-156

  • Local Institution - 826

    Krakow, 31-501

  • Local Institution - 834

    Ksawerów, 95-054

  • Local Institution - 581

    Lodz, 90-127

  • Local Institution - 829

    Lodz, 90-302

  • Local Institution - 888

    Lodz, 91-839

  • Local Institution - 981

    Lodz, 93-034

  • Local Institution - 760

    Lublin, 20-049

  • Local Institution - 976

    Nowy Targ, 34-400

  • Local Institution - 830

    Olsztyn, 10-561

  • Local Institution - 402

    Opole, 45-819

  • Local Institution - 400

    Oświęcim, 32-600

  • Local Institution - 758

    Poznan, 60-529

  • Local Institution - 575

    Poznan, 60-702

  • Local Institution - 401

    Poznan, 61-293

  • Local Institution - 963

    Rzeszów, 35-302

  • Local Institution - 979

    Sopot, 81-756

  • Local Institution - 239

    Sopot, 81756

  • Local Institution - 835

    Szczecin, 71-270

  • Local Institution - 235

    Szczecin, 71434

  • Local Institution - 822

    Torun, 87-100

  • Local Institution - 824

    Tychy, 43-100

  • Local Institution - 827

    Ul. Piotrkowska 177, 90-447

  • Local Institution - 410

    Warsaw, 00-189

  • Local Institution - 576

    Warsaw, 01-192

  • Local Institution - 833

    Warsaw, 02-018

  • Local Institution - 989

    Warsaw, 02-653

  • Local Institution - 236

    Warsaw, 04-501

  • Local Institution - 586

    Warsaw, 04-501

  • Local Institution - 807

    Warsaw, 04-730

  • Local Institution - 893

    Wierzchosławice, 33-122

  • Local Institution - 983

    Wroclaw, 50-053

  • Local Institution - 984

    Wroclaw, 50-367

  • Local Institution - 582

    Wroclaw, 50-381

  • Local Institution - 982

    Wroclaw, 51-162

  • Local Institution - 831

    Wroclaw, 53-114

  • Local Institution - 987

    Wroclaw, 53-333

  • Local Institution - 832

    Wroclaw, 54-144

  • Local Institution - 403

    Zamość, Lublin Voivodeship, 22-400

  • Local Institution - 597

    Zamość, Lublin Voivodeship, 22-400

Other trials in Poland

Russia53 sites

  • Local Institution - 871

    Barnaul, 656024

  • Local Institution - 589

    Bataysk, 346880

  • Local Institution - 621

    Chelyabinsk, 454021

  • Local Institution - 991

    Chelyabinsk, 454076

  • Local Institution - 598

    Chita, 672090

  • Local Institution - 848

    Irkutsk, 664049

  • Local Institution - 998

    Kaliningrad, 236016

  • Local Institution - 882

    Kaluga, 248007

  • Local Institution - 892

    Kazan', 420103

  • Local Institution - 849

    Kemerovo, 650066

  • Local Institution - 599

    Khanty-Mansiysk, 628012

  • Local Institution - 927

    Krasnoyarsk, 660037

  • Local Institution - 566

    Moscow, 105554

  • Local Institution - 851

    Moscow, 111123

  • Local Institution - 873

    Moscow, 117997

  • Local Institution - 870

    Moscow, 119192

  • Local Institution - 869

    Moscow, 123423

  • Local Institution - 990

    Nizhny Novgorod, 603140

  • Local Institution - 594

    Novosibirsk, 630007

  • Local Institution - 853

    Novosibirsk, 630091

  • Local Institution - 876

    Novosibirsk, 630117

  • Local Institution - 996

    Omsk, 644024

  • Local Institution - 875

    Orenburg, 460050

  • Local Institution - 867

    Penza, 440026

  • Local Institution - 858

    Petrozavodsk, 185019

  • Local Institution - 859

    Pushkin, 196603

  • Local Institution - 960

    Pyatigorsk, 357502

  • Local Institution - 846

    Pyatigorsk, 357538

  • Local Institution - 863

    Saint Petersburg, 191015

  • Local Institution - 993

    Saint Petersburg, 191015

  • Local Institution - 862

    Saint Petersburg, 194044

  • Local Institution - 868

    Saint Petersburg, 194044

  • Local Institution - 847

    Saint Petersburg, 194354

  • Local Institution - 857

    Saint Petersburg, 195009

  • Local Institution - 845

    Saint Petersburg, 195067

  • Local Institution - 856

    Saint Petersburg, 195257

  • Local Institution - 879

    Saint Petersburg, 196143

  • Local Institution - 878

    Saint Petersburg, 196247

  • Local Institution - 874

    Saint Petersburg, 197110

  • Local Institution - 865

    Samara, 443001

  • Local Institution - 844

    Samara, 443041

  • Local Institution - 866

    Sochi, 354207

  • Local Institution - 877

    Tomsk, 634063

  • Local Institution - 806

    Tula, 300053

  • Local Institution - 881

    Ufa, 450005

  • Local Institution - 861

    Ufa, 450071

  • Local Institution - 855

    Velikiy Novgorod, 173008

  • Local Institution - 935

    Vladimir, 600023

  • Local Institution - 999

    Vladivostok, 690091

  • Local Institution - 986

    Vladivostok, 690922

  • Local Institution - 880

    Volgograd, 400107

  • Local Institution - 583

    Yekaterinburg, 620075

  • Local Institution - 872

    Yekaterinburg, 620109

Other trials in Russia

Ukraine38 sites

  • Local Institution - 914

    Chernivtsi, 58001

  • Local Institution - 922

    Chernivtsi, 58001

  • Local Institution - 950

    Dnipropetrovsk, 49074

  • Local Institution - 229

    Ivano-Frankivsk, 76008

  • Local Institution - 929

    Ivano-Frankivsk, 76008

  • Local Institution - 912

    Ivano-Frankivsk, 76018

  • Local Institution - 919

    Kharkiv, 61018

  • Local Institution - 965

    Kharkiv, 61037

  • Local Institution - 920

    Khmelnytskyi, 29000

  • Local Institution - 933

    Kropyvnytskyi, 25006

  • Local Institution - 901

    Kyiv, 01030

  • Local Institution - 923

    Kyiv, 01601

  • Local Institution - 915

    Kyiv, 02000

  • Local Institution - 243

    Kyiv, 02002

  • Local Institution - 563

    Kyiv, 02002

  • Local Institution - 911

    Kyiv, 02175

  • Local Institution - 244

    Kyiv, 03037

  • Local Institution - 564

    Kyiv, 03037

  • Local Institution - 918

    Kyiv, 04053

  • Local Institution - 908

    Kyiv, 04107

  • Local Institution - 977

    Kyiv, 04107

  • Local Institution - 562

    Kyiv, 4210

  • Local Institution - 240

    Lutsk, 43005

  • Local Institution - 590

    Lutsk, 43005

  • Local Institution - 234

    Lviv, 79010

  • Local Institution - 974

    Lviv, 79010

  • Local Institution - 910

    Lviv, 79059

  • Local Institution - 242

    Odesa, 65025

  • Local Institution - 902

    Odesa, 65025

  • Local Institution - 905

    Poltava, 36011

  • Local Institution - 934

    Ternopil, 46008

  • Local Institution - 909

    Vinnytsia, 02029

  • Local Institution - 932

    Vinnytsia, 21009

  • Local Institution - 224

    Vinnytsia, 21018

  • Local Institution - 924

    Vinnytsia, 21018

  • Local Institution - 971

    Vinnytsia, 21018

  • Local Institution - 587

    Zaporizhia, 69063

  • Local Institution - 925

    Zaporizhzhya, 69600

Other trials in Ukraine

China36 sites

  • Local Institution - 482

    Beijing, 100050

  • Local Institution - 467

    Beijing, 100700

  • Local Institution - 379

    Bengbu, 233004

  • Local Institution - 485

    Changchun, 130021

  • Local Institution - 376

    Changchun, 130033

  • Local Institution - 421

    Changsha, 410008

  • Local Institution - 378

    Changsha, 450052

  • Local Institution - 423

    Changzhou, Jiangsu, 213003

  • Local Institution - 414

    Changzhou, 213004

  • Local Institution - 419

    Chengdu, Sichuan, 610041

  • Local Institution - 422

    Fuzhou, 350005

  • Local Institution - 478

    Guangzhou, 510030

  • Local Institution - 472

    Guangzhou, 510180

  • Local Institution - 486

    Guangzhou, 510655

  • Local Institution - 470

    Hangzhou, Zhejiang, 100142

  • Local Institution - 491

    Hefei, 230001

  • Local Institution - 374

    Kunming, 650032

  • Local Institution - 383

    Luzhou, 646099

  • Local Institution - 488

    Nanchang, 330006

  • Local Institution - 418

    Nanjing, 210008

  • Local Institution - 375

    Nanjing, 210009

  • Local Institution - 487

    Nanjing, 210029

  • Local Institution - 369

    Shanghai, Shanghai Municipality, 200120

  • Local Institution - 473

    Shanghai, 200025

  • Local Institution - 380

    Shanghai, 200040

  • Local Institution - 377

    Shanghai, 200080

  • Local Institution - 416

    Shanghai, 200092

  • Local Institution - 458

    Taichung City, 40447

  • Local Institution - 373

    Tianjin, 300052

  • Local Institution - 475

    Wuhan, 430022

  • Local Institution - 474

    Wuhan, 430030

  • Local Institution - 483

    Wuhan, 430060

  • Local Institution - 381

    Wuxi, 214023

  • Local Institution - 415

    Xi'an, 710038

  • Local Institution - 420

    Xi'an, 710100

  • Local Institution - 370

    Zhengzhou, 450014

Other trials in China

Germany30 sites

  • Local Institution - 626

    Berlin, 10117

  • Local Institution - 629

    Berlin, 10787

  • Local Institution - 665

    Berlin, 10825

  • Local Institution - 653

    Berlin, 12200

  • Local Institution - 648

    Berlin, 13353

  • Local Institution - 650

    Berlin, 14050

  • Local Institution - 628

    Berlin, 14163

  • Local Institution - 664

    Brandenburg an der Havel, 14770

  • Local Institution - 732

    Dachau, 85221

  • Local Institution - 662

    Frankfurt, 60431

  • Local Institution - 654

    Frankfurt, 60594

  • Local Institution - 574

    Frankfurt am Main, 60313

  • Local Institution - 657

    Frankfurt am Main, 60590

  • Local Institution - 658

    Halle, 06108

  • Local Institution - 656

    Halle, 06120

  • Local Institution - 659

    Hamburg, 20246

  • Local Institution - 652

    Hamburg, 22559

  • Local Institution - 591

    Hanover, 30625

  • Local Institution - 649

    Keil, 24105

  • Local Institution - 337

    Leipzig, 04103

  • Local Institution - 651

    Leipzig, 04103

  • Local Institution - 655

    Ludwigshafen am Rhein, 67067

  • Local Institution - 730

    Ludwigshafen am Rhein, 67067

  • Local Institution - 660

    Mainz, 55131

  • Local Institution - 667

    Münster, 48149

  • Local Institution - 620

    Neuruppin, 16816

  • Local Institution - 584

    Nürtingen, 72622

  • Local Institution - 661

    Stuttgart, 70376

  • Local Institution - 666

    Tübingen, 72076

  • Local Institution - 663

    Ulm, 89081

Other trials in Germany

Australia26 sites

  • Local Institution - 308

    Adelaide, South Australia, 5000

  • Local Institution - 708

    Adelaide, South Australia, 5112

  • Local Institution - 325

    Bankstown, 2200

  • Local Institution - 307

    Bedford Park, South Australia, 5042

  • Local Institution - 330

    Box Hill, 3128

  • Local Institution - 317

    Clayton, Victoria, 3168

  • Local Institution - 310

    Concord, New South Wales, 2139

  • Local Institution - 326

    Elizabeth Vale, South Australia, 05112

  • Local Institution - 305

    Fitzroy, Victoria, 3065

  • Local Institution - 329

    Geelong, Victoria, 3220

  • Local Institution - 328

    Herston, Queensland, 4029

  • Local Institution - 319

    Kingswood, New South Wales, 2747

  • Local Institution - 309

    Liverpool, New South Wales, 2170

  • Local Institution - 707

    Maroochydore, Queensland, 4558

  • Local Institution - 313

    Maroorchydore, Queensland, 4558

  • Local Institution - 327

    Melbourne, Victoria, 3004

  • Local Institution - 709

    Melbourne, Victoria, 3004

  • Local Institution - 316

    Murdoch, Western Australia, 6150

  • Local Institution - 318

    New Lambton Heights, New South Wales, 2305

  • Local Institution - 321

    North Mackay, Queensland, 4740

  • Local Institution - 312

    South Brisbane, Queensland, 4101

  • Local Institution - 315

    Subiaco, Western Australia, 6008

  • Local Institution - 324

    Sydney, NSW, NSW 2050

  • Local Institution - 323

    Wollongong, New South Wales, 2500

  • Local Institution - 320

    Woodville South, South Australia, 5011

  • Local Institution - 311

    Woolloongabba, Queensland, 4102

Other trials in Australia

Italy20 sites

  • Local Institution - 677

    Bologna, 40138

  • Local Institution - 684

    Brescia, 25123

  • Local Institution - 688

    Brescia, 25124

  • Local Institution - 689

    Castellana Grotte, 70013

  • Local Institution - 679

    Catanzaro, 88100

  • Local Institution - 687

    Chieti, 66100

  • Local Institution - 674

    Messina, 98125

  • Local Institution - 672

    Milan, 20089

  • Local Institution - 686

    Milan, 20122

  • Local Institution - 334

    Milan, 20132

  • Local Institution - 678

    Monza, 20900

  • Local Institution - 685

    Padova, 35128

  • Local Institution - 682

    Palermo, 90146

  • Local Institution - 673

    Pavia, 27100

  • Local Institution - 681

    Roma, 00133

  • Local Institution - 675

    Roma, 00168

  • Local Institution - 671

    Rome, 00152

  • Local Institution - 680

    Udine, 33100

  • Local Institution - 670

    Varese, 21100

  • Local Institution - 676

    Verona, 37024

Other trials in Italy

Canada18 sites

  • Local Institution - 256

    Brandon, Manitoba, R7A 0N7

  • Local Institution - 268

    Bridgewater, Nova Scotia, B4V 3N2

  • Local Institution - 273

    Calgary, Alberta, T2N 4Z6

  • Local Institution - 227

    Edmonton, Alberta, T5R 1W2

  • Local Institution - 269

    Edmonton, Alberta, T5R1W2

  • Local Institution - 266

    Greater Sudbury, Ontario, P3C 5K6

  • Local Institution - 263

    Kelowna, British Columbia, V1Y 1Z9

  • Local Institution - 252

    London, Ontario, N6A 5A5

  • Local Institution - 251

    London, Ontario, N6A 5W9

  • Local Institution - 254

    Montreal, Quebec, H1T 2M4

  • Local Institution - 262

    New Westminster, British Columbia, V3L 3W5

  • Local Institution - 270

    Ottawa, Quebec, K1H 8L6

  • Local Institution - 264

    Toronto, Ontario, M5G 1X5

  • Local Institution - 257

    Toronto, Ontario, M5T 3A9

  • Local Institution - 255

    Vancouver, British Columbia, V5Z1M9

  • Local Institution - 267

    Vancouver, British Columbia, V6Z 2K5

  • Local Institution - 271

    Vaughan, Ontario, L4L 4Y7

  • Local Institution - 261

    Winnipeg, Manitoba, R3CON2

Other trials in Canada

France18 sites

  • Local Institution - 638

    Amiens, 80054

  • Local Institution - 639

    Béziers, 34525

  • Local Institution - 635

    Blois, 41016

  • Local Institution - 634

    Caen, 14000

  • Local Institution - 644

    Colombes, 92701

  • Local Institution - 711

    Créteil, 94010

  • Local Institution - 616

    Dijon, 21079

  • Local Institution - 615

    Grenoble, 38700

  • Local Institution - 633

    Lillie Cedex, 59037

  • Local Institution - 646

    Marseille, 13915

  • Local Institution - 507

    Montpellier, 34295

  • Local Institution - 632

    Nantes, 44093

  • Local Institution - 647

    Neuilly-sur-Seine, Cedex, 92200

  • Local Institution - 630

    Pierre-Bénite, 69495

  • Local Institution - 641

    Rennes, 35033

  • Local Institution - 612

    Rouen, 76031

  • Local Institution - 631

    Saint-Priest-en-Jarez, 42270

  • Local Institution - 643

    Toulouse, 31059

Other trials in France

Georgia18 sites

  • Local Institution - 786

    Batumi, 6010

  • Local Institution - 779

    Kutaisi, 4600

  • Local Institution - 248

    Tbilisi, 0101

  • Local Institution - 454

    Tbilisi, 0101

  • Local Institution - 783

    Tbilisi, 0101

  • Local Institution - 247

    Tbilisi, 0112

  • Local Institution - 778

    Tbilisi, 0112

  • Local Institution - 782

    Tbilisi, 0131

  • Local Institution - 552

    Tbilisi, 0144

  • Local Institution - 781

    Tbilisi, 0159

  • Local Institution - 793

    Tbilisi, 0159

  • Local Institution - 740

    Tbilisi, 0160

  • Local Institution - 784

    Tbilisi, 0160

  • Local Institution - 785

    Tbilisi, 0160

  • Local Institution - 335

    Tbilisi, 0179

  • Local Institution - 249

    Tbilisi, 0180

  • Local Institution - 455

    Tbilisi, 0180

  • Local Institution - 780

    Telavi, 2200

Other trials in Georgia

Spain16 sites

  • Local Institution - 703

    Alicante, 03010

  • Local Institution - 690

    Badalona, 08916

  • Local Institution - 694

    Barcelona, 08022

  • Local Institution - 702

    Córdoba, 14001

  • Local Institution - 699

    Girona, 17007

  • Local Institution - 701

    Las Palmas de Gran Canaria, 35012

  • Local Institution - 691

    Madrid, 28006

  • Local Institution - 695

    Madrid, 28040

  • Local Institution - 692

    Madrid, 28046

  • Local Institution - 693

    Majadahonda, Madrid, 28222

  • Local Institution - 698

    San Cristóbal de La Laguna, 38320

  • Local Institution - 706

    Santander, 39008

  • Local Institution - 696

    Seville, 41009

  • Local Institution - 705

    Seville, 41013

  • Local Institution - 697

    Valencia, 46010

  • Local Institution - 700

    Viladecans, 08840

Other trials in Spain

South Korea15 sites

  • Local Institution - 437

    Ansan, 152-703

  • Local Institution - 441

    Busan, 49201

  • Local Institution - 434

    Busan, 49241

  • Local Institution - 431

    Busan, 612-030

  • Local Institution - 432

    Daegu, 705-030

  • Local Institution - 435

    Guri-si, 11923

  • Local Institution - 436

    Seongnam-si, 13620

  • Local Institution - 433

    Seoul, 06351

  • Local Institution - 440

    Seoul, 06591

  • Local Institution - 430

    Seoul, 120-752

  • Local Institution - 442

    Seoul, 138-736

  • Local Institution - 438

    Seoul, 3080

  • Local Institution - 427

    Seoul, 3181

  • Local Institution - 439

    Seoul, 7985

  • Local Institution - 429

    Suwon, 442723

Other trials in South Korea

United Kingdom15 sites

  • Local Institution - 557

    Birmingham, B15 2SQ

  • Local Institution - 714

    Bristol, BS2 8HW

  • Local Institution - 560

    Cardiff, CF15 9SS

  • Local Institution - 558

    Chorley, PR7 7NA

  • Local Institution - 559

    Corbridge Road, NE46 1QJ

  • Local Institution - 712

    Dundonald, BT16 1RH

  • Local Institution - 713

    Glasgow, G51 4TF

  • Local Institution - 716

    Lancashire Blackpool, FY3 8NR

  • Local Institution - 729

    London, LND, NW1 2BU

  • Local Institution - 722

    London, E1 1BB

  • Local Institution - 715

    London, SE1 9RT

  • Local Institution - 561

    North Manchester Science Park, M15 6SX

  • Local Institution - 593

    Shrewsbury, SY38XQ

  • Local Institution - 723

    Southampton, Hampshire, SO16 6YD

  • Local Institution - 718

    Torquay, TQ2 7AA

Other trials in United Kingdom

Bulgaria14 sites

  • Local Institution - 456

    Blagoevgrad, 2700

  • Local Institution - 746

    Plovdiv, 4002

  • Local Institution - 753

    Rousse, 7002

  • Local Institution - 747

    Sofia, 1202

  • Local Institution - 750

    Sofia, 1407

  • Local Institution - 755

    Sofia, 1407

  • Local Institution - 756

    Sofia, 1431

  • Local Institution - 627

    Sofia, 1527

  • Local Institution - 752

    Sofia, 1527

  • Local Institution - 749

    Sofia, 1606

  • Local Institution - 554

    Sofia, 1784

  • Local Institution - 748

    Sofia, 1784

  • Local Institution - 553

    Stara Zagora, 6000

  • Local Institution - 754

    Varna, 9002

Other trials in Bulgaria

Czechia12 sites

  • Local Institution - 767

    Brno, 615 00

  • Local Institution - 772

    Brno, 656 91

  • Local Institution - 773

    Hradec Králové, 500 12

  • Local Institution - 775

    Most, 43401

  • Local Institution - 771

    Olomouc, 77900

  • Local Institution - 774

    Pardubice, 532 03

  • Local Institution - 769

    Pilsen, 30460

  • Local Institution - 573

    Prague, 120 00

  • Local Institution - 368

    Prague, 14000

  • Local Institution - 776

    Prague, 14021

  • Local Institution - 768

    Prague, 150 06

  • Local Institution - 770

    Prague, 190 00

Other trials in Czechia

Israel12 sites

  • Local Institution - 343

    Afula, 18341

  • Local Institution - 345

    Bat Yam, 5962025

  • Local Institution - 346

    Beer Jacob, 73100

  • Local Institution - 350

    Haifa, 3109601

  • Local Institution - 339

    Jerusalem, 91031

  • Local Institution - 347

    Jerusalem, 9362410

  • Local Institution - 349

    Kfar Saba, 44281

  • Local Institution - 344

    Nahariya, 22100

  • Local Institution - 341

    Petah Tikva, 49100

  • Local Institution - 342

    Ramat Gan, 52621

  • Local Institution - 338

    Rehovot, 76100

  • Local Institution - 340

    Tel Aviv, 64239

Other trials in Israel

Serbia12 sites

  • Local Institution - 241

    Belgrade, 11 000

  • Local Institution - 245

    Belgrade, 11 080

  • Local Institution - 887

    Belgrade, 11 080

  • Local Institution - 246

    Belgrade, 11000

  • Local Institution - 596

    Belgrade, 11000

  • Local Institution - 886

    Belgrade, 11000

  • Local Institution - 890

    Belgrade, 11000

  • Local Institution - 891

    Kragujevac, 34000

  • Local Institution - 884

    Novi Sad, 21 000

  • Local Institution - 885

    Pančevo, 26000

  • Local Institution - 585

    Vršac, 26300

  • Local Institution - 889

    Zrenjanin, 23 000

Other trials in Serbia

Argentina11 sites

  • Local Institution - 501

    Buenos Aires, 0

  • Local Institution - 494

    Buenos Aires, 1180

  • Local Institution - 571

    Buenos Aires, 1702

  • Local Institution - 500

    Buenos Aires, B1878

  • Local Institution - 570

    Córdoba, X5003DCE

  • Local Institution - 495

    Córdoba, X5016

  • Local Institution - 569

    Mar del Plata, B7600

  • Local Institution - 496

    Rosario, 2000

  • Local Institution - 497

    Rosario, 2000

  • Local Institution - 502

    Rosario, Santa Fe, S2002

  • Local Institution - 492

    San Miguel de Tucumán, 4000

Other trials in Argentina

Hungary11 sites

  • Local Institution - 798

    Békéscsaba, 5600

  • Local Institution - 803

    Budapest, 1062

  • Local Institution - 804

    Budapest, 1088

  • Local Institution - 556

    Budapest, H-1036

  • Local Institution - 801

    Győr, 9024

  • Local Institution - 555

    Gyula, 5700

  • Local Institution - 797

    Miskolc, 3529

  • Local Institution - 800

    Nagykanizsa, H-8800

  • Local Institution - 799

    Székesfehérvár, 8000

  • Local Institution - 816

    Szekszárd, 7100

  • Local Institution - 805

    Szentes, 6600

Other trials in Hungary

India11 sites

  • Local Institution - 408

    Coimbatore, Tamil Nadu, 641044

  • Local Institution - 457

    Delhi, 110002

  • Local Institution - 332

    Gurgaon, Haryana, 122002

  • Local Institution - 444

    Hyderabad, Andhra Pradesh, 500084

  • Local Institution - 331

    Hyderabad, Telangana, 500032

  • Local Institution - 443

    Jaipur, Rajasthan, 302004

  • Local Institution - 399

    Jaipur, Rajasthan, 302006

  • Local Institution - 445

    Kochi, Kerala, 682041

  • Local Institution - 446

    Ludhiana, Punjab, 141001

  • Local Institution - 411

    New Delhi, 110029

  • Local Institution - 407

    Surat, Gujarat, 395002

Other trials in India

Turkey (Türkiye)11 sites

  • Local Institution - 357

    Ankara, 01660

  • Local Institution - 356

    Ankara, 06590

  • Local Institution - 360

    Bursa, 16059

  • Local Institution - 365

    Elâzığ, 23119

  • Local Institution - 362

    Istanbul, 34093

  • Local Institution - 358

    Istanbul, 34098

  • Local Institution - 361

    Istanbul, 34668

  • Local Institution - 355

    Istanbul, 34840

  • Local Institution - 354

    Izmit/Kocaeli, 41380

  • Local Institution - 353

    Kadiköy/Istanbul, 41380

  • Local Institution - 359

    Trabzon, 61080

Other trials in Turkey (Türkiye)

Mexico10 sites

  • Local Institution - 528

    Chihuahua City, 31020

  • Local Institution - 527

    México, 07020

  • Local Institution - 448

    Mexico City, 6700

  • Local Institution - 532

    Monterrey, Nuevo León, 64610

  • Local Institution - 525

    Monterrey, Nuevo León, 64718

  • Local Institution - 447

    Monterrey, Nuevo León, C.P 64000

  • Local Institution - 449

    Monterrey, Nuevo León, C.P 64060

  • Local Institution - 529

    Querétaro City, Querétaro, 76070

  • Local Institution - 530

    Tlalpan, 14080

  • Local Institution - 526

    Zapapan, Jalisco, 45030

Other trials in Mexico

Romania10 sites

  • Local Institution - 808

    Bucharest, 010719

  • Local Institution - 836

    Bucharest, 010719

  • Local Institution - 499

    Bucharest, 013823

  • Local Institution - 795

    Bucharest, 021494

  • Local Institution - 837

    Bucharest, 022328

  • Local Institution - 839

    Bucharest, 050098

  • Local Institution - 842

    Bucharest, 10825

  • Local Institution - 838

    Cluj-Napoca, 400001

  • Local Institution - 843

    Craiova, 200642

  • Local Institution - 840

    Târgu Mureş, 540136

Other trials in Romania

Belgium8 sites

  • Local Institution - 943

    Brasschaat, Antwerpen, 2930

  • Local Institution - 940

    Brussels, 1090

  • Local Institution - 939

    Edegem, 2650

  • Local Institution - 937

    Ghent, 9000

  • Local Institution - 942

    Leuven, 3000

  • Local Institution - 936

    Liège, 4000

  • Local Institution - 938

    Seraing, 4100

  • Local Institution - 941

    Tournai, 7500

Other trials in Belgium

Greece8 sites

  • Local Institution - 790

    Athens, 11 527

  • Local Institution - 588

    Athens, 115 28

  • Local Institution - 791

    Athens, 11527

  • Local Institution - 792

    Athens, 18536

  • Local Institution - 592

    Athens, Attiki, 15562

  • Local Institution - 787

    Heraklion, 71 110

  • Local Institution - 789

    Thessaloniki, 54642

  • Local Institution - 788

    Thessaloniki, 56429

Other trials in Greece

Taiwan8 sites

  • Local Institution - 460

    Kaohsiung City, 82445

  • Local Institution - 463

    Kaohsiung, San Ming Dist., 807

  • Local Institution - 363

    Kozlu, 67000

  • Local Institution - 461

    Niao-Sung Hsiang Kaohsiung County, 83301

  • Local Institution - 459

    Tainan, Taiana, 704

  • Local Institution - 462

    Taoyuan City, 33305

  • Local Institution - 465

    Tapei, 10002

  • Local Institution - 464

    Tapei, Beitou Dist., 11217

Other trials in Taiwan

Slovakia7 sites

  • Local Institution - 900

    Bratislava, 820 07

  • Local Institution - 894

    Bratislava, 82606

  • Local Institution - 895

    Brezno, 97701

  • Local Institution - 899

    Nitra, 94901

  • Local Institution - 897

    Nové Zámky, 94002

  • Local Institution - 898

    Prešov, 080 01

  • Local Institution - 896

    Rimavská Sobota, 979 01

Other trials in Slovakia

South Africa7 sites

  • Local Institution - 543

    Gauteng, 1820

  • Local Institution - 545

    Kempton Park, 1619

  • Local Institution - 544

    Pretoria, 0001

  • Local Institution - 542

    Pretoria, 0084

  • Local Institution - 549

    Pretoria, 0181

  • Local Institution - 548

    Somerset West, 7130

  • Local Institution - 547

    Val de Grace, 0184

Other trials in South Africa

Croatia6 sites

  • Local Institution - 453

    Koprivnica, 48000

  • Local Institution - 763

    Osijek, 31000

  • Local Institution - 765

    Split, HR-21000

  • Local Institution - 452

    Zagreb, 10000

  • Local Institution - 762

    Zagreb, 10000

  • Local Institution - 766

    Zagreb, 10000

Other trials in Croatia

Netherlands6 sites

  • Local Institution - 952

    Amsterdam, 1081 HV

  • Local Institution - 955

    Amsterdam, 1105 AZ

  • Local Institution - 956

    Groningen, 9713 GZ

  • Local Institution - 949

    Nijmegen, 6525 GA

  • Local Institution - 951

    Sittard-Geleen, 6162 BG

  • Local Institution - 954

    Tilburg, 5022 GC

Other trials in Netherlands

Chile5 sites

  • Local Institution - 389

    Concepción, 4070038

  • Local Institution - 392

    Santiago, 7500010

  • Local Institution - 387

    Santiago, 7500571

  • Local Institution - 391

    Santiago, 7550000

  • Local Institution - 390

    Santiago, 8320000

Other trials in Chile

Colombia5 sites

  • Local Institution - 397

    Armenia, Quindío Department, 630004

  • Local Institution - 398

    Barranquilla, 080020

  • Local Institution - 395

    Bogotá, 110221

  • Local Institution - 396

    Cali, 760026

  • Local Institution - 394

    Medellín, 050034

Other trials in Colombia

Lithuania5 sites

  • Local Institution - 605

    Kaunas, LT-50009

  • Local Institution - 603

    Klaipėda, LT-5808

  • Local Institution - 607

    Vilnius, 08406

  • Local Institution - 606

    Vilnius, LT-08661

  • Local Institution - 604

    Vilnius, LT-10207

Other trials in Lithuania

Austria4 sites

  • Local Institution - 726

    Innsbruck, 6020

  • Local Institution - 727

    Sankt Pölten, 3100

  • Local Institution - 336

    Vienna, 1020

  • Local Institution - 725

    Vienna, 1090

Other trials in Austria

Bosnia and Herzegovina4 sites

  • Local Institution - 743

    Banja Luka, 78000

  • Local Institution - 741

    Mostar, 88000

  • Local Institution - 738

    Sarajevo, 71000

  • Local Institution - 742

    Sarajevo, 71000

Other trials in Bosnia and Herzegovina

Moldova4 sites

  • Local Institution - 811

    Chisinau, MD-2068

  • Local Institution - 809

    Chisinau, MD2025

  • Local Institution - 812

    Chisinau, MD2025

  • Local Institution - 813

    Chisinau, MD2025

Other trials in Moldova

Portugal4 sites

  • Local Institution - 959

    Coimbra, 3000-075

  • Local Institution - 958

    Guimarães, 4835-044

  • Local Institution - 961

    Loures, 2674-514

  • Local Institution - 957

    Viana do Castelo, 4904-858

Other trials in Portugal

Saudi Arabia4 sites

  • Local Institution - 534

    Dammam, 32253

  • Local Institution - 537

    Jeddah, 22252

  • Local Institution - 536

    Riyadh, 12746

  • Local Institution - 535

    Riyadh, 14611

Other trials in Saudi Arabia

Denmark3 sites

  • Local Institution - 611

    Copenhagen, 2400

  • Local Institution - 610

    Holbæk, 4300

  • Local Institution - 609

    Nykøbing Falster, 4800

Other trials in Denmark

Latvia3 sites

  • Local Institution - 602

    Riga, LV-1002

  • Local Institution - 601

    Riga, LV-1006

  • Local Institution - 600

    Riga, LV-1038

Other trials in Latvia

Switzerland3 sites

  • Local Institution - 967

    Bern, 3001

  • Local Institution - 968

    Sankt Gallen, 9007

  • Local Institution - 969

    Zurich, 8091

Other trials in Switzerland

Belarus2 sites

  • Local Institution - 745

    Grodno, 230026

  • Local Institution - 737

    Vitebsk, 210604

Other trials in Belarus

Finland2 sites

  • Local Institution - 613

    Helsinki, 00290

  • Local Institution - 614

    Turku, FI-20521

Other trials in Finland

Hong Kong2 sites

  • Local Institution - 404

    Hong Kong, 0

  • Local Institution - 405

    Kowloon, 0

Other trials in Hong Kong

Ireland2 sites

  • Local Institution - 975

    Dublin, Dublin, DO4 T6F4

  • Local Institution - 973

    Dublin, D09 V2N0

Other trials in Ireland

Senegal1 site

  • Local Institution - 546

    Cape Town, 7500

Other trials in Senegal

Slovenia1 site

  • Local Institution - 904

    Celje, 3000

Other trials in Slovenia

Sweden1 site

  • Local Institution - 625

    Stockholm, 112 81

Other trials in Sweden

About this study

Official title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

This is a study to demonstrate the effect of oral ozanimod as maintenance therapy in participants with moderately to severely active Crohn's Disease.

Conditions
Crohn Disease
Being tested
Ozanimod, Placebo
Keywords
Crohn's Disease, Crohn Disease, Oral, Ozanimod, Moderately active, Severely active, RPC01, RPC01-3203
Medical subject headings
Crohn Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • OzanimodDrug

    Specified dose on specified days

  • PlaceboOther

    Specified dose on specified days

Study groups in NCT03464097
Study groupRoleWhat they receive
OzanimodExperimentalNot described
Receives: Drug: Ozanimod
PlaceboPlacebo comparatorNot described
Receives: Other: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants Who Achieve Crohn's Disease Activity Index (CDAI) Score < 150 at Week 52 as Observed

    The CDAI is a composite score that is used to measure the clinical activity of Crohn's disease (CD). The CDAI uses a questionnaire with 8 disease activity variables: number of soft/liquid stools, severity of abdominal pain, general well-being, presence of complications, need for antidiarrheal drugs, presence of an abdominal mass, hematocrit, and deviation in body weight. The sub scores of number of soft/liquid stool, severity of abdominal pain (0 \[none\] to 3 \[Severe\]), general well-being (0 \[well\] to 4 \[terrible\] were summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome.

    Measured: Week 52

  2. Percentage of Participants With a Simple Endoscopic Score for Crohn's Disease (SES-CD) Score Decrease From Baseline ≥ 50% Based on Observed Cases and Robarts Observed Scores

    The SES-CD assessed the degree of inflammation. The SES-CD assesses the following 4 components: size of ulcers, ulcerated surface, affected surface, and presence of narrowing. Each of these components was scored on a scale of 0 (none/unaffected) to 3 (worst). In the SES-CD, each of these 4 components are assessed in the five segments: ileum, right colon, transverse colon, left colon, and rectum. The SES-CD was the sum of the individual scores of each of the components across the five segments. The range of SES-CD scores was 0 - 12 for each segment, and 0 - 60 for the overall SES-CD score, with larger scores indicating greater degree of inflammation. Baseline was defined as the last assessment prior to the start time of the first drug administration if time of measurement is available else the last assessment prior to or on the date of the first drug administration.

    Measured: Week 52

Secondary outcomes (15)

  1. Percentage of Participants With CDAI Reduction From Baseline ≥ 100 Points or CDAI Score <150 at Week 52 as Observed

    The CDAI is a composite score that is used to measure the clinical activity of Crohn's disease (CD). The CDAI uses a questionnaire with 8 disease activity variables: number of soft/liquid stools, severity of abdominal pain, general well-being, presence of complications, need for antidiarrheal drugs, presence of an abdominal mass, hematocrit, and deviation in body weight. The sub scores of number of soft/liquid stool, severity of abdominal pain (0 \[none\] to 3 \[Severe\]), general well-being (0 \[well\] to 4 \[terrible\] were summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome.

    Measured: Week 52

  2. Percentage of Participants With Average Daily Abdominal Pain Score ≤1point and Average Daily Stool Frequency ≤ 3 Points With Abdominal Pain and Stool Frequency no Worse Than Baseline at Week 52

    Abdominal pain (AP) and stool frequency (SF) clinical remission was defined as average daily abdominal pain score ≤ 1 point, and average daily stool frequency ≤3 times with AP and SF no worse than baseline at Week 12. Participants entered responses in diaries daily. The 7 days entries prior to visit were considered for calculating average AP score and SF. The AP was graded on severity of 0 (none) to 3 (severe) scale and SF was defined number of liquid or soft stools per day.

    Measured: Week 52

  3. Percentage of Participants With With CDAI Score < 150 at Week 52, While Remaining Corticosteroid Free in the 12 Weeks Prior to Week 52 Among All Participants at Maintenance Day 1

    Abdominal pain (AP) and stool frequency (SF) clinical remission was defined as average daily abdominal pain score ≤ 1 point, and average daily stool frequency ≤3 times with AP and SF no worse than baseline at Week 12. Participants entered responses in diaries daily. The 7 days entries prior to visit were considered for calculating average AP score and SF. The AP was graded on severity of 0 (none) to 3 (severe) scale and SF was defined number of liquid or soft stools per day.

    Measured: Week 52

  4. Percentage of Participants With CDAI Score < 150 at Week 52 in Participants With CDAI Score <150 at Maintenance Day 1

    The CDAI is a composite score that is used to measure the clinical activity of Crohn's disease (CD). The CDAI uses a questionnaire with 8 disease activity variables: number of soft/liquid stools, severity of abdominal pain, general well-being, presence of complications, need for antidiarrheal drugs, presence of an abdominal mass, hematocrit, and deviation in body weight. The sub scores of number of soft/liquid stool, severity of abdominal pain (0 \[none\] to 3 \[Severe\]), general well-being (0 \[well\] to 4 \[terrible\] were summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome.

    Measured: Week 52

  5. Percentage of Participants With Simple Endoscopic Score for Crohn's Disease (SES-CD) ≤ 4 Points and SES-CD Decrease From Baseline ≥ 2points With no SES-CD Subscore > 1 Point at Week 52 Based on Observed Cases

    The SES-CD score is a way to measure how severe a person's bowel disease is. It looks at five different parts of the bowel and checks for ulcer size, ulcerated surface, inflamed surface, and stenosis. Each is given a score from 0 to 3 based on how bad the disease is. These scores are then added together for a total score ranging from 0 to 60. Higher scores indicate more severe disease.

    Measured: Week 52

  6. Percentage of Participants With CDAI Score < 150 and SES-CD Decrease From Baseline ≥50% at Week 52 Based on Observed Cases and Robarts Observed Scores

    CDAI is a composite score used to measure the clinical activity of Crohn's disease (CD). It assess 8 disease activity variables: number of soft/liquid stools, severity of abdominal pain, general well-being, presence of complications, need for antidiarrheal drugs, presence of an abdominal mass, hematocrit, and deviation in body weight. Sub scores of number of soft/liquid stool, severity of abdominal pain (0 \[none\] to 3 \[Severe\]), general well-being (0 \[well\] to 4 \[terrible\] were summed over the 7 days prior to each visit. Remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome. SES-CD score is a way to measure how severe a person's bowel disease is. It looks at five different parts of the bowel. Each is given a score from 0 to 3 based on how bad the disease is. These scores are then added together for a total score ranging from 0 to 60. Higher scores indicate more severe disease.

    Measured: Week 52

  7. Percentage of Participants With Average Daily AP Score ≤ 1 Point, and Average Daily Stool Frequency Score ≤ 3 Points With AP and SF no Worse Than Baseline and SES-CD ≤ 4 Points and SES-CD Decrease ≥2 Points With no SES-CD Subscore >1 Point at Week 52

    Abdominal pain (AP) and stool frequency (SF) clinical remission was defined as average daily abdominal pain score ≤ 1 point, and average daily stool frequency ≤ 3 times with AP and SF no worse than baseline at Week 12. Participants entered responses in diaries daily. The 7 days entries prior to visit were considered for calculating average AP score and SF. The AP was graded on severity of 0 (none) to 3 (severe) scale and SF was defined number of liquid or soft stools per day. The SES-CD has 4 components size of ulcers, ulcerated surface, affected surface, presence of narrowing. Each component was scored on scale of 0 (none) to 3 (worst). In SES-CD, each of 4 components are assessed in the five segments: ileum, right, transverse, left colon, and rectum. The SES-CD was the sum of the individual scores of each of the components across the five segments. The range of SES-CD scores was 0 - 12 for each segment, and 0 - 60 for overall, with larger scores show greater degree of inflammation.

    Measured: Week 52

  8. Percentage of Participants With CDAI Reduction From Baseline ≥ 100 Points or CDAI Score <150 and SES-CD Decrease From Baseline ≥ 50% at Week 52

    CDAI is a composite score used to measure the clinical activity of Crohn's disease (CD). It assess 8 disease activity variables: number of soft/liquid stools, severity of abdominal pain, general well-being, presence of complications, need for antidiarrheal drugs, presence of an abdominal mass, hematocrit, and deviation in body weight. Sub scores of number of soft/liquid stool, severity of abdominal pain (0 \[none\] to 3 \[Severe\]), general well-being (0 \[well\] to 4 \[terrible\] were summed over the 7 days prior to each visit. Remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome. SES-CD score is a way to measure how severe a person's bowel disease is. It looks at five different parts of the bowel. Each is given a score from 0 to 3 based on how bad the disease is. These scores are then added together for a total score ranging from 0 to 60. Higher scores indicate more severe disease.

    Measured: Week 52

  9. Percentage of Participants With CDAI Reduction From Baseline ≥ 70 Points at Week 52 Based on Observed Cases

    CDAI is a composite score used to measure the clinical activity of Crohn's disease (CD). It assess 8 disease activity variables: number of soft/liquid stools, severity of abdominal pain, general well-being, presence of complications, need for antidiarrheal drugs, presence of an abdominal mass, hematocrit, and deviation in body weight. Sub scores of number of soft/liquid stool, severity of abdominal pain (0 \[none\] to 3 \[Severe\]), general well-being (0 \[well\] to 4 \[terrible\] were summed over the 7 days prior to each visit. Remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome.

    Measured: Week 52

  10. Percentage of Participants With With CDAI Score < 150 at Week 52, While Remaining Corticosteroid Free in the 12 Weeks Prior to Week 52 Among Subjects Using Corticosteroids at Maintenance Day 1

    CDAI is a composite score used to measure the clinical activity of Crohn's disease (CD). It assess 8 disease activity variables: number of soft/liquid stools, severity of abdominal pain, general well-being, presence of complications, need for antidiarrheal drugs, presence of an abdominal mass, hematocrit, and deviation in body weight. Sub scores of number of soft/liquid stool, severity of abdominal pain (0 \[none\] to 3 \[Severe\]), general well-being (0 \[well\] to 4 \[terrible\] were summed over the 7 days prior to each visit. Remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome.

    Measured: Week 52

  11. Percentage of Participants With Mucosal Healing (SES-CD ≤ 4 Points and SES-CD Decrease ≥2 Points With no SES-CD Subscore > 1 Point) and Histologic Improvement Based on Robarts Histologic Index (RHI) at Week 52

    The SES-CD assessed the degree of inflammation. The SES-CD assesses the following 4 components: size of ulcers, ulcerated surface, affected surface, and presence of narrowing. Each of these components was scored on a scale of 0 (none/unaffected) to 3 (worst). In the SES-CD, each of these 4 components are assessed in the five segments: ileum, right colon, transverse colon, left colon, and rectum. The SES-CD was the sum of the individual scores of each of the components across the five segments. The range of SES-CD scores was 0 - 12 for each segment, and 0 - 60 for the overall SES-CD score, with larger scores indicating greater degree of inflammation. Baseline was defined as the last assessment prior to the start time of the first drug administration if time of measurement is available else the last assessment prior to or on the date of the first drug administration.

    Measured: Week 52

  12. Time to Relapse (an Increase in CDAI Score From Maintenance Day 1 ≥100 Points and CDAI Score >220, SES-CD ≥ 6 [or ≥4 if Isolated Ileal Disease]), and Exclusion of Other Causes of an Increase in Disease Activity Unrelated to Underlying CD

    CDAI is a composite score used to measure the clinical activity of Crohn's disease (CD). It assess 8 disease activity variables: number of soft/liquid stools, severity of abdominal pain, general well-being, presence of complications, need for antidiarrheal drugs, presence of an abdominal mass, hematocrit, and deviation in body weight. Sub scores of number of soft/liquid stool, severity of abdominal pain (0 \[none\] to 3 \[Severe\]), general well-being (0 \[well\] to 4 \[terrible\] were summed over the 7 days prior to each visit. Remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome. SES-CD score is a way to measure how severe a person's bowel disease is. It looks at five different parts of the bowel. Each is given a score from 0 to 3 based on how bad the disease is. These scores are then added together for a total score ranging from 0 to 60. Higher scores indicate more severe disease.

    Measured: Week 52

  13. Percentage of Participants With a Crohn's Disease Endoscopic Index of Severity (CDEIS) Decrease From Baseline ≥ 50% at Week 52

    CDEIS is an index for determining the severity of Crohn's disease with endoscopic localization to ileum and colon. The CDEIS divides the intestine into 5 segments: rectum, sigmoid and left colon, transverse colon, right colon, and ileum. Four variables are assessed in each segment: the presence of deep ulceration, the presence of superficial ulceration, the percentage of ulcerated surface, and the percentage of surface affected by CD, indicated on 10-cm visual analogue scales. In addition, the presence of ulcerated stenosis and the presence of nonulcerated stenosis are also assessed over the entire intestine. These factors are weighted and summed to calculate the total score ranging from 0- 44, with higher scores indicating more severe disease.

    Measured: Week 52

  14. Percentage of Participants With CDAI Score < 150 at Week 52 and at ≥ 80% of Visits Between Week 8 and Week 52, Inclusive, in Participants With CDAI Score < 150 at Maintenance Day 1

    The CDAI is a composite score that is used to measure the clinical activity of Crohn's disease (CD). The CDAI uses a questionnaire with 8 disease activity variables: number of soft/liquid stools, severity of abdominal pain, general well-being, presence of complications, need for antidiarrheal drugs, presence of an abdominal mass, hematocrit, and deviation in body weight. The sub scores of number of soft/liquid stool, severity of abdominal pain (0 \[none\] to 3 \[Severe\]), general well-being (0 \[well\] to 4 \[terrible\] were summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome.

    Measured: Week 52

  15. Percentage of Participants With Average Daily Abdominal Pain Score ≤ 1 Point and Average Daily Stool Frequency Score ≤3 Points With Abdominal Pain and Stool Frequency no Worse Than Baseline and SES-CD Decrease From Baseline ≥ 50% at Week 52

    Abdominal pain (AP) and stool frequency (SF) clinical remission was defined as average daily abdominal pain score ≤ 1 point, and average daily stool frequency ≤3 times with AP and SF no worse than baseline. Participants entered responses in diaries daily. The 7 days entries prior to visit were considered for calculating average AP score and SF. The AP was graded on severity of 0 (none) to 3 (severe) scale and SF was defined number of liquid or soft stools per day. SES-CD score is a way to measure how severe a person's bowel disease is. It looks at five different parts of the bowel. Each is given a score from 0 to 3 based on how bad the disease is. These scores are then added together for a total score ranging from 0 to 60. Higher scores indicate more severe disease.

    Measured: Week 52

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Mar 2018
  2. Study start27 Jun 2018
  3. Primary completion3 Oct 2024
  4. Study completion3 Oct 2024

Why it stopped: The study has terminated due to non-safety reasons; Business Objectives have changed.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
550 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03464097
Sponsor's protocol ID
RPC01-3203
Other IDs
U1111-1203-8002, 2023-510426-33, 2023
Status last verified
Sep 2025
First submitted
26 Feb 2018
Last updated
9 Oct 2025
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No

Publications

  • Feagan BG, Schreiber S, Afzali A, Rieder F, Hyams J, Kollengode K, Pearlman J, Son V, Marta C, Wolf DC, D'Haens GG. Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial program. Contemp Clin Trials. 2022 Nov;122:106958. doi: 10.1016/j.cct.2022.106958. Epub 2022 Oct 5.

    PubMed 36208720

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Ozanimod in people with Crohn Disease, run by Celgene at 765 sites in 49 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 9 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 765 sites in United States, Poland, Russia, Ukraine, China and 44 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 9 Oct 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants Who Achieve Crohn's Disease Activity Index (CDAI) Score < 150 at Week 52 as Observed (time frame: Week 52). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03464097, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Oct 2025; AzTrials last refreshed its copy on 7 Nov 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in